Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
CONCLUSION: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.PMID:37743180 | DOI:10.1016/j.clml.2023.08.018
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Sundar Jagannath Sosana Delimpasi Sebastian Grosicki Dane R Van Domelen Ohad S Bentur Ivan Špička Meletios A Dimopoulos Source Type: research
More News: Anemia | Cancer & Oncology | Dexamethasone | Lymphoma | Myeloma | Study | Thrombocytopenia | Velcade